Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.
about
Biomarkers of Parkinson's disease: present and futureGut Feelings About α-Synuclein in Gastrointestinal Biopsies: Biomarker in the Making?Microglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic MiceIs Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.Oculo-Visual Dysfunction in Parkinson's Disease.Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's diseaseArguing against the proposed definition changes of PDHow Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend InitiativeAre Upper-Body Axial Symptoms a Feature of Early Parkinson's Disease?Default mode network differences between rigidity- and tremor-predominant Parkinson's diseaseDiagnosing and treating neurogenic orthostatic hypotension in primary care.Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease DementiaPremotor and nonmotor features of Parkinson's disease.Motor output variability, deafferentation, and putative deficits in kinesthetic reafference in Parkinson's diseaseMDS clinical diagnostic criteria for Parkinson's disease.MDS research criteria for prodromal Parkinson's disease.Eryptosis as a marker of Parkinson's diseaseUnbiased approaches to biomarker discovery in neurodegenerative diseasesNaturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.Nursing interventions for rehabilitation in Parkinson's disease: cross mapping of terms.Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trialsClinical correlations with Lewy body pathology in LRRK2-related Parkinson diseaseMotor Subtype as a Predictor of Future Working Memory Performance in Idiopathic Parkinson's Disease.Propagated but Topologically Distributed Forebrain Neurons Expressing Alpha-Synuclein in Aged Macaques"Gunslinger's gait": a new cause of unilaterally reduced arm swing.Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysisPathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology.Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson's Disease.Gastrointestinal Dysfunctions in Parkinson's Disease: Symptoms and Treatments.Inflammation in Parkinson's disease: role of glucocorticoids.Cinnamamide Derivatives for Central and Peripheral Nervous System Disorders--A Review of Structure-Activity Relationships.Advanced stages of PD: interventional therapies and related patient-centered care.The relevance of pre-motor symptoms in Parkinson's disease.The Concept of Prodromal Parkinson's Disease.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory systemɑ-Synuclein strains and the variable pathologies of synucleinopathies.
P2860
Q24170134-B80E0B1E-E231-47BD-A06E-4527A671BE29Q26769620-C5F4B9DE-8528-474A-A0DD-6399D4A72F24Q26773064-DA719571-4965-4EDE-98A4-3B4A8ABFAC98Q26801733-BE775EAC-43B5-4657-9F6A-15615918333CQ27322513-2E82E8C7-8A48-4109-ACF1-69A707EDC879Q27691337-1F86C15F-4B2B-492B-ADA6-CC1595411AEAQ28071861-E6FF72E0-E49C-4E2C-88DF-11BB578A9B7BQ28079237-2133A1E1-701C-4FDD-85C6-7B89359CE97BQ28601451-2203274C-3592-4504-8E12-A9D005B7B00AQ30372617-AE5C66C6-3F1C-471A-B2D2-DB1CF41B4C38Q30843485-C5DC3DF7-CE67-4106-8893-6D9C8F82575FQ33165773-F732AD29-E9F0-4FBD-9EE7-A3C25A59C9BBQ33562458-2074425B-2527-4505-9005-918565B47804Q34274224-F205CF95-22E7-43FD-BB60-761620F1A082Q34377411-142E3930-72C9-4E59-9AE5-737E6631C88FQ34498274-93D77909-BED4-44D0-B1B4-C7F64917F0B4Q34498279-083BF9D4-F781-48C7-AEA7-5E718F05D121Q34585744-2B434D00-74A4-4EEC-96D4-CF6AD228261CQ34625918-FAD5E9DC-047F-4CE8-B452-0BB3F9C2D282Q34627859-4EAC8208-DBA8-483F-A00C-97009E586C77Q34678262-9076E85C-20FA-4745-A345-C1ED9F9D01A0Q35211066-E8A02CB1-90D1-4447-BA67-6B5A3EFD5FE7Q35442728-90F20B7F-9E33-43E5-9E3E-28EF409B9852Q35970595-6643DCCB-6884-4AB6-9545-5327B10F5A4CQ36197708-605A4FD3-2C52-41D5-B097-7A5F1F6733AFQ36369299-06836442-911F-4DB2-8FFB-AA9511CA6F89Q36419572-B41A5187-FD7F-4531-94A6-30AB7C4FB14EQ36581696-263A9074-C516-42D9-A84B-4095AD82D3FCQ37129119-3C3D6BD0-65E5-4D8A-AB95-DED33472026FQ37141684-6186EA1A-E7EB-4D99-AFDE-BF7F642FA8FCQ37274056-370B6B72-EBC8-418F-B82B-F2E1E11FFB14Q37516494-47234BF8-E7BE-41D7-8C79-A8F304209321Q38425458-CBEA6E9A-39F9-4296-92FA-35C5170F233CQ38530238-681C4B6D-8075-42F7-9948-CD4C90721B1AQ38542180-3B91850C-F823-4AE8-9425-610909C1763BQ38594857-89456271-09D0-4605-B538-803017B07F33Q38612230-A684F739-4AD9-4C0C-99A8-09EF475DB342Q38636630-D5C699FA-FB6B-4B28-A26B-4424170B9AD1Q38752945-E5D22B22-6936-4368-99A7-BC6FA1629FFEQ38753941-CADCF30E-9D4C-473F-9D8C-3C27196DAD13
P2860
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@ast
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@en
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@nl
type
label
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@ast
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@en
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@nl
prefLabel
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@ast
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@en
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
Time to redefine PD? Introduct ...... nition of Parkinson's disease.
@en
P2093
Glenda M. Halliday
José Obeso
Kenneth Marek
Matthew Stern
Ronald B. Postuma
P2860
P304
P3181
P356
10.1002/MDS.25844
P407
P50
P5008
P577
2014-04-01T00:00:00Z